Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 21Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 4Triple Negative Breast Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Patient Preference 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1

Interventions

pertuzumab 1pazopanib 1enzalutamide 1delta 24-sterol reductase 1decitabine and cedazuridine drug combination 1daratumumab 1apalutamide 1Validation Studies as Topic 1Trastuzumab 1Tape Recording 1Surgical Procedures, Operative 1Sunitinib 1Sorafenib 1Risk Assessment 1Radiotherapy 1Preoperative Exercise 1Pilot Projects 1Opdualag 1Nutritional Support 1Nivolumab 1Injections, Subcutaneous 1Focus Groups 1Exercise 1Ethanol 1Bandages, Hydrocolloid 1Ado-Trastuzumab Emtansine 1Adiposity 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Patient Preference × decitabine and cedazuridine drug combination × Clear all
NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡